New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
By targeting the TTR gene directly in the liver, the therapy “has opened up the door” to permanent treatment, says Sarah ...
An open-label extension study of the phase 3 ATTRibute-CM trial shows that acoramidis produced reductions of 36% and 34% in ...
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback